Cambrian Biopharma Closes $100 Million Series C To Advance Healthspan-Boosting Therapeutics To The Clinic

Oct 26, 2021•almost 4 years ago

Amount Raised

$100 Million

Round Type

series c

Description

Cambrian Biopharma, a multi-asset longevity biotech, today announced the close of an oversubscribed Series C financing, which raised $100 million. The financing was co-led by Anthos Capital and SALT Fund, with participation from existing investors Apeiron Investment Group, Future Ventures, Moore Capital and others, to develop therapeutics to combat the biological drivers of aging, treat and prevent age-related diseases and lengthen healthspan. With this financing, Cambrian has raised approximately $160 million since the company was founded in 2019.

Company Information

Company

Cambrian Biopharma

About

Cambrian Biopharma is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. To date, Cambrian has 14 novel therapeutics in development across its majority-held pipeline companies. For more information, please visit www.cambrianbio.com or follow us on Twitter @CambrianBio and LinkedIn.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech